Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Jefferies Downgrades Calliditas Therapeutics (CALT) to Hold
May 28, 2024 1:15 PM EDTJefferies analyst Maury Raycroft downgraded Calliditas Therapeutics (NASDAQ: CALT) from Buy to Hold with a price target of $39.00 (from $58.00).
The analyst comments "Asahi Kasei (JPX:3407-T) to acquire CALT for ~$39/ADS (current $38) for ~$1.1B. Transaction was unanimously approved by both cos'... More
Stifel Downgrades Calliditas Therapeutics (CALT) to Hold
May 28, 2024 9:45 AM EDTStifel analyst Annabel Samimy downgraded Calliditas Therapeutics (NASDAQ: CALT) from Buy to Hold with a price target of $40.00 (from $55.00).
The analyst comments "Underscoring the increasing activity in nephrology, and specifically IgAN, Asahi Kasei has offered ¥3,076/SEK208/share of CALT or SEK416/ADR... More
